摘要
Ex-RAD(ON01210)是近几年由美军联合昂克诺瓦制药公司研发的新型高效、低毒抗辐射药物。由于其显著的生存率和低毒性,已于2008年被美国FDA批准进行Ⅰ期临床试验。本文结合近年文献,对Ex-RAD的结构、合成路线、检测方法及药理作用等进行综述,探讨Ex-RAD的应用前景。
Ex-RAD （ON01210） is a novel and efficient anti-radiation drug with low toxicity developed by US army and Onconova Pharmaceuticals in recent years. The significant survival advantage and low toxicity of Ex-RAD have contributed to the approval by the FDA as an investigational new drug in December 2008. Meanwhile, the drug is currently in phase I clinical trials in humans. In this paper, the chemical structure, synthesis mute, detection method and pharmacological action of Ex-RAD were reviewed, and the application prospect of Ex-RAD was also explored.
作者
井娟
王力彬
冯甜
张书锋
黄海英
刘畅
李想
郝勇
Jing Juan Wang Libin Feng Tian Zhang Shufeng Huang Haiying Liu Chang Li Xiang Hao Yong(Bethune Medical NCO School, Shijiazhuang 050083, China Department of Medicinal Chemistry, School of Pharmacy, the Fourth Military Medical University Student Brigade, the Fourth Military Medical University)
出处
《中国药师》
CAS
2017年第9期1631-1633,共3页
China Pharmacist
关键词
Ex-RAD
抗电离辐射
含量测定
药理作用
Ex-RAD
Anti-ionizing radiation
Content determination
Pharmacological effects
